Abstract Library

#1871 Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines

Introduction: Su has shown PFS improvement in patients (pt) with PNET in phase III trial

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marconcini R

Authors: Marconcini R, Bloise F, Pusceddu S, Femia D, Bongiovanni A,

Keywords: sunitinib,

#1421 Oxaliplatin-based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors

Introduction: The role of chemotherapy in low/intermediate grade neuroendocrine tumors (NETs) is still debated.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Spada F

Authors: Spada F, Antonuzzo L, Marconcini R, Radice D, Antonuzzo A,

Keywords: Oxaliplatin, NETs,

#1401 Everolimus (EV) Plus Somatostatin Analog (SSA) Administered Before or After Chemotherapy (CT) or PRRT in Advanced G1-G2 Neuroendocrine Tumor (NET): A Single Center Experience

Introduction: In metastatic NET G1-G2 progressed after SSA, many treatment are appropriated including EV, CT and PRRT. However, there are no studies guiding the appropriate sequence of treatments.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Antonuzzo A, Luca G, Vasile E,

Keywords: everolimus SSA,

#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET

Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Galli L, Antonuzzo A, Vasile E,

Keywords: capecitabine, oxaliplatine ,

#1110 Chemotherapy with Capecitabine plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Neoplasms (NENs): An Italian Multicenter Retrospective Analysis

Introduction: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in pancreatic neuroendocrine neoplasms (pNENs).

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Spada F

Authors: Spada F, Antonuzzo L, Marconcini R, Gelsomino F, Fumagalli C,

Keywords: NEN, NET, chemotherapy,